Efalizumab-associated papular psoriasis

Archives of Dermatology

Volumn 143, Issue 7, 2007, Pages 900-906

  Hassan, Akmal S ^a   Simon, Dagmar ^a   Simon, Hans Uwe ^a   Braathen, Lasse R ^a   Yawalkar, Nikhil ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB;

ADULT; ARTICLE; CASE REPORT; EFALIZUMAB ASSOCIATED PAPULAR PSORIASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 34447506592     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.7.900     Document Type: Article

References (14)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9): 581-588.
2. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(suppl 2):ii30-ii36.
3. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138(5):591-600.
4. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003; 349(21):2004-2013.
5. Gordon KB, Papp KA, Hamilton TK, et al; Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290(23):3073-3080.
6. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141(1):31-38.
7. Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. 2006; 54(4)(suppl 1):S182-S188.
8. Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54(4)(suppl 1):S171-S181.
9. Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg. 2005;24(1):19-27.
10. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. 2004; 114(4):887-895.
11. Tan B, Foley P. Guttate psoriasis following Ecstasy ingestion. Australas J Dermatol. 2004;45(3):167-169.
12. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol. 1998;16(3):333-351.
13. Gaspari AA. Innate and adaptive immunity in the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(3)(suppl 2):S67-S80.
14. Raptiva (efalizumab) [package insert]. South San Francisco, CA: Genentech Inc; 2003.